SubsidieMeestersEngineering and Delivering B Cells Using Biomaterials against Breast Cancer
END-BC aims to enhance B cell adoptive cell therapy for breast cancer using novel biomaterials to improve efficacy, reduce side effects, and lower treatment costs.
Projectdetails
Introduction
Breast cancer (BC) is the most diagnosed cancer worldwide, and despite treatment availability, the disease remains challenging to treat, causing substantial adverse side effects and fatalities globally. The lack of efficacy and inaccessibility of standard care supports this demand for better treatments.
Current Challenges
This is demonstrated by resection surgery and current (neo)adjuvant therapies such as chemotherapy exhibiting inadequacies, resulting in 30% of BC patients having metastases. These percentages are even higher in low human index regions due to inaccessibility, cost, and growing populations.
Emerging Solutions
Adoptive cell therapy (ACT), such as CAR-T, is a category of emerging immunotherapies expected to impact oncology by transferring engineered immune cells into a patient to eliminate cancer cells. However, these treatments are currently ineffective in BC and costly.
Project Overview
END-BC will complement research into B cells to produce an ACT that improves treatment efficacy against breast cancer while reducing side effects and costs from effective therapy. Our research developed novel biomaterial to overcome significant obstacles to successfully enhance B cell functions against cancer using a low-cost method.
Research Goals
In END-BC, we will research the commercial and technical feasibility of tailoring the B cell ACT with biomaterials to determine its potential to treat BC.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-1-2024 |
| Einddatum | 30-6-2025 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSITAETSKLINIKUM AACHENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Engineering B cells to fight cancerThis project aims to develop a novel cancer immunotherapy using engineered B cells to enhance anti-tumor responses through targeted gene integration and localized immune activation. | ERC Consolid... | € 1.996.250 | 2022 | Details |
B Cell Engineering and Tertiary Lymphoid Structure Induction via Biomaterials for Cancer ImmunotherapyBeaT-IT seeks to enhance cancer immunotherapy by optimizing B cell activation and tertiary lymphoid structure formation using nano-/biomaterials for improved tumor treatment outcomes. | ERC Starting... | € 1.488.762 | 2022 | Details |
Chemical Engineering of Natural Killer Cells for Cancer ImmunotherapyThis project aims to develop a faster, cheaper method for producing chemically engineered immune cells for cancer immunotherapy, comparing it to traditional CAR-NK cell approaches. | ERC Proof of... | € 150.000 | 2022 | Details |
Modular Targeted Nanoplatform for Immune Cell Regulation and TherapyImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative. | ERC Proof of... | € 150.000 | 2023 | Details |
Chimeric Antigen Receptor (CAR) T Cell Therapy For Solid TumorsCAR-T(uning) aims to enhance CAR-T therapy for NSCLC by improving treatment persistence and reducing tumor immunosuppression, paving the way for effective, broadly applicable cancer therapies. | ERC Proof of... | € 150.000 | 2022 | Details |
Engineering B cells to fight cancer
This project aims to develop a novel cancer immunotherapy using engineered B cells to enhance anti-tumor responses through targeted gene integration and localized immune activation.
B Cell Engineering and Tertiary Lymphoid Structure Induction via Biomaterials for Cancer Immunotherapy
BeaT-IT seeks to enhance cancer immunotherapy by optimizing B cell activation and tertiary lymphoid structure formation using nano-/biomaterials for improved tumor treatment outcomes.
Chemical Engineering of Natural Killer Cells for Cancer Immunotherapy
This project aims to develop a faster, cheaper method for producing chemically engineered immune cells for cancer immunotherapy, comparing it to traditional CAR-NK cell approaches.
Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy
ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.
Chimeric Antigen Receptor (CAR) T Cell Therapy For Solid Tumors
CAR-T(uning) aims to enhance CAR-T therapy for NSCLC by improving treatment persistence and reducing tumor immunosuppression, paving the way for effective, broadly applicable cancer therapies.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
PRO CellecTPan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Activeerbare Anti-Kanker ImmunotherapieHet project onderzoekt de haalbaarheid van een nieuw medicijnconcept door een prototype van een activeerbare BiTE te ontwikkelen en te evalueren op concurrentievermogen met bestaande technologieën. | Mkb-innovati... | € 20.000 | 2020 | Details |
CAR T cells Rewired to prevent EXhaustion in the tumour microenvironmentCAR T-REX aims to enhance CAR T cell efficacy against solid tumors by integrating auto-regulated genetic circuits to prevent exhaustion, using advanced gene editing and delivery technologies. | EIC Pathfinder | € 2.733.931 | 2023 | Details |
Bottom-up manufacturing of artificial anti-tumor T cellsThe project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment. | EIC Pathfinder | € 3.391.796 | 2024 | Details |
Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell ReprogrammingThe Repro-TIL project aims to enhance tumor-reactive TIL expansion for more effective immunotherapy in solid tumors, paving the way for improved treatment outcomes and commercialization. | EIC Transition | € 2.480.367 | 2025 | Details |
PRO CellecT
Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.
Activeerbare Anti-Kanker Immunotherapie
Het project onderzoekt de haalbaarheid van een nieuw medicijnconcept door een prototype van een activeerbare BiTE te ontwikkelen en te evalueren op concurrentievermogen met bestaande technologieën.
CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment
CAR T-REX aims to enhance CAR T cell efficacy against solid tumors by integrating auto-regulated genetic circuits to prevent exhaustion, using advanced gene editing and delivery technologies.
Bottom-up manufacturing of artificial anti-tumor T cells
The project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment.
Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell Reprogramming
The Repro-TIL project aims to enhance tumor-reactive TIL expansion for more effective immunotherapy in solid tumors, paving the way for improved treatment outcomes and commercialization.